Clinical Trials

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer


Study ID
Genentech CO39303

NCT Number
NCT03072238 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0336

Principle Investigator
Dr. Robert Alter

Phase
III

Sponsor
Genentech


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now